T. Rowe Price Associates (TWST) discloses 3.63M-share Twist Bioscience position

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. reported beneficial ownership of 3,634,470 shares of Twist Bioscience Corp.5.8% of the company’s common stock. T. Rowe Price Associates reported sole voting power over 3,520,536 shares and sole dispositive power over 3,634,470 shares, with no shared voting or dispositive power. The firm is organized in Maryland and states that this filing should not be construed as an admission that it is the beneficial owner of the referenced securities, and such beneficial ownership is expressly denied.

Key Figures

Shares beneficially owned: 3,634,470 shares Percent of class: 5.8% Sole voting power: 3,520,536 shares +3 more

6 metrics

Shares beneficially owned 3,634,470 shares Amount beneficially owned in Twist Bioscience common stock reported on Schedule 13G

Percent of class 5.8% Percentage of Twist Bioscience common stock represented by reported holdings

Sole voting power 3,520,536 shares Shares over which T. Rowe Price Associates has sole power to vote

Sole dispositive power 3,634,470 shares Shares over which T. Rowe Price Associates has sole power to dispose

CUSIP 90184D100 CUSIP number for Twist Bioscience Corp. common stock

Signature date 08/14/2026 Date the Schedule 13G was signed by the reporting person’s vice president

Key Terms

Schedule 13G, beneficial ownership, sole voting power, dispositive power, +1 more

5 terms

Schedule 13G regulatory

"reported beneficial ownership of 3,634,470 shares of common stock on a Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial ownership financial

"Amount beneficially owned: 3634470 (b) | Percent of class: 5.8 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole voting power financial

"Sole power to vote or to direct the vote: 3520536"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole power to dispose or to direct the disposition of: 3634470"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

CUSIP Number financial

"Title of class of securities: COMMON STOCK (e) | CUSIP Number(s): 90184D100"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

FAQ

What percentage of Twist Bioscience (TWST) does T. Rowe Price Associates report owning?

T. Rowe Price Associates reports beneficial ownership of 5.8% of Twist Bioscience’s common stock, based on 3,634,470 shares reported on a Schedule 13G filing.

How many Twist Bioscience (TWST) shares does T. Rowe Price Associates report on its Schedule 13G?

T. Rowe Price Associates reports 3,634,470 shares of Twist Bioscience common stock as beneficially owned, corresponding to 5.8% of the outstanding class of common stock.

What voting power does T. Rowe Price Associates have over Twist Bioscience (TWST) shares?

T. Rowe Price Associates reports sole voting power over 3,520,536 shares of Twist Bioscience and no shared voting power, according to the Schedule 13G ownership disclosure.

What dispositive power does T. Rowe Price Associates report for its Twist Bioscience (TWST) holdings?

The firm reports sole dispositive power over 3,634,470 shares of Twist Bioscience common stock and no shared dispositive power, indicating control over decisions to sell or otherwise dispose of these shares.

Does T. Rowe Price Associates admit beneficial ownership of its Twist Bioscience (TWST) position?

T. Rowe Price Associates states that the filing should not be construed as an admission of beneficial ownership of the reported securities, and that such beneficial ownership is expressly denied in the disclosure.

What class of Twist Bioscience (TWST) securities is covered by this Schedule 13G?

The Schedule 13G covers common stock of Twist Bioscience Corp., identified by CUSIP 90184D100, with T. Rowe Price Associates reporting its position in that security class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 10:40 AM Accepted by SEC EDGAR 08/14/2026 - 10:38 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TWIST BIOSCIENCE CORP

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

90184D100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 90184D100

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,520,536.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,634,470.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,634,470.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TWIST BIOSCIENCE CORP
(b)	Address of issuer's principal executive offices: 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 90184D100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3634470
(b)	Percent of class: 5.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3520536
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3634470
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2026